Testing of new agents in childhood cancer preclinical models: Meeting summary

Clinical Cancer Research

Volumn 8, Issue 12, 2002, Pages 3646-3657

  Houghton, Peter J ^a   Adamson, Peter C ^b   Blaney, Susan ^c   Fine, Howard A ^d   Gorlick, Richard ^e   Haber, Michelle ^f   Helman, Lee ^g   Hirschfeld, Steve ^h   Hollingshead, Melinda G ⁱ   Israel, Mark A ^j   Lock, Richard B ^f   Maris, John M ^b   Merlino, Glenn ^g   Patterson, Wendy ^g   Reynolds, C Patrick ^k   Shannon, Kevin ^l   Yu, Alice ^m   Yu, John ⁿ   Smith, Malcolm A ^g  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d Medical Neurology Branch   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g NATIONAL CANCER INSTITUTE   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j DARTMOUTH MEDICAL SCHOOL   (United States)

^k CHILDREN S HOSPITAL LOS ANGELES   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UCSD MEDICAL CENTER   (United States)

ⁿ SCRIPPS RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOSTATISTICS; CHILDHOOD CANCER; CORRELATION ANALYSIS; DISEASE MODEL; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; UNITED STATES; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASMS;

EID: 0036896670     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Pharmaceutical Research and Manufacturers of America. New Medicines in Development for Cancer 2001. Washington, DC: Pharmaceutical Research and Manufacturers of America, 2001.
2. Houghton, P. J., Horton, J. K., and Houghton, J. A. Drug sensitivity and resistance in the xenograft model. In: H. M. Maurer, F. B. Ruymann, and C. Pochedly (eds.), CRC Rhabdomyosarcoma and Related Tumors in Children and Adolescents, pp. 187-203. Boca Raton, FL: CRC Press, 1991.
3. Horowitz, M. E., Etcubanas, E., Christensen, M. L., Houghton, J. A., George, S. L., Green, A. A., and Houghton, P. J. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: A model for anticancer drug development. J. Clin. Oncol., 6: 308-314, 1988.
4. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
5. Pappo, A. S., Lyden, E., Breneman, J., Wiener, E., Teot, L., Meza, J., Crist, W., and Vietti, T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J. Clin. Oncol., 19: 213-219, 2001.
6. Kretschmar, C., Kletzel, M., Murray, K., Joshi, V., Smith, E., Pao, P., and Castleberry, R. Upfront Phase II therapy with Taxol and topotecan in untreated children (>365 days) with disseminated (INSS stage 4) neuroblastoma: a Pediatric Oncology Group study. Med. Pediatr. Oncol., 25: 243, 1995.
7. Keshelava, N., Seeger, R. C., Groshen, S., and Reynolds, C. P. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res., 58: 5396-5405, 1998.
8. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., and Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 83: 757-766, 1991.
9. Scherf, U., Ross. D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., Scudiero, D. A., Eisen, M. B., Sausville, E. A., Pommier, Y., Botstein, D., Brown, P. O., and Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 24: 236-244, 2000.
10. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 82: 1113-1118. 1990.
11. Keshelava, N., Groshen, S., and Reynolds, C. P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother. Pharmacol., 45: 1-8, 2000.
12. Keshelava. N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res., 61: 6185-6193, 2001.
13. Anderson, C. P., Keshelava, N., Satake, N., Meek, W. H., and Reynolds, C. P. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med. Pediatr. Oncol., 35: 659-662, 2000.
14. Maurer. B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (Bethesda), 92: 1897-1909, 2000.
15. Omura-Minamisawa, M., Diccianni, M. B., Batova, A., Chang, R. C., Bridgeman, L. J., Yu, J., de Wit, E., Kung, F. H., Pullen, J. D., and Yu, A. L. In vitro sensitivity of T-cell lymphoblastic leukemia to UCN-01 (7-hydroxystaurosporine) is dependent on p16 protein status: a Pediatric Oncology Group study. Cancer Res., 60: 6573-6576, 2000.
16. Batova, A., Diccianni, M. B., Omura-Minamisawa, M., Yu, J., Carrera, C. J., Bridgeman, L. J., Kung, F. H., Pullen, J., Amylon, M. D., and Yu, A. L. Use of alanosine as a methylthioadenosine phosphorylaseselective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res., 59: 1492-1497, 1999.
17. Zamboni, W. C., Stewart, C. F., Thompson, J., Santana, V. M., Cheshire, P. J., Richmond, L. B., Luo, X., Poquette, C., Houghton, J. A., and Houghton, P. J. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J. Natl. Cancer Inst. (Bethesda), 90: 505-511, 1998.
18. Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B., Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer, F. A., Meyer, W. H., Pappo, A. S., Walter, A. W., and Houghton, P. J. Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J. Clin. Oncol., 17: 1815-1824, 1999.
19. Shusterman, S., Grupp, S. A., Barr, R., Carpentieri, D., Zhao, H., and Maris, J. M. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res., 7: 977-984, 2001.
20. νintegrin antagonist. Neurosurgery, 48: 151-157, 2001.
21. Soffer, S. Z., Moore, J. T., Kim. E., Huang, J., Yokoi, A., Manley, C., O'Toole, K., Stolar, C., Middlesworth, W., Yamashiro, D. J., and Kandel, J. J. Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg., 36: 1177-1181, 2001.
22. Rowe, D. H., Huang, J., Kayton, M. L., Thompson, R., Troxel, A., O'Toole, K. M., Yamashiro, D., Stolar, C. J., and Kandel, J. J. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J. Pediatr. Surg., 35: 30-32, 2000.
23. Evans, A. E., Kisselbach, K. D., Yamashiro. D. J., Ikegaki, N., Camoratto, A. M., Dionne, C. A., and Brodeur, G. M. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res., 5: 3594-3602, 1999.
24. Houghton, P. J., Cheshire, P. J., and Harwood, F. C. Evaluation of ZD1839 (Iressa) alone and in combination with irinotecan (CPT-11) against pediatric solid tumor xenografts. Clin. Cancer Res., 6: (Suppl. 11): 379, 2000.
25. Lock, R. B., Liem, N., Farnsworth, M. L., Milross, C., Collins, C., and Rice, A. M. Suitability of the NOD/SCID mouse for engraftment and chemosensitivity testing of childhood acute lymphoblastic leukemia. Proc. Am. Assoc. Cancer Res., 42: 480-481, 2001.
26. Dialynas, D. P., Shao, L., Billman, G. F., and Yu, J. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood. Stem Cells, 19: 443-452, 2001.
27. Dialynas, D. P., Lee, M. J., Gold, D. P., Shao, L., Yu, A. L., Borowitz, M. J., and Yu, J. Preconditioning with fetal cord blood facilitates engraftment of primary childhood T-cell acute lymphoblastic leukemia in immunodeficient mice. Blood, 97: 3218-3225. 2001.
28. Lock, R. B., Liem, N., Farnsworth, M. L., Milross, C. G., Xue, C., Tajbakhsh, M., Haber, M., Norris, M. D., Marshall, G. M., and Rice, A. M. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood, 99: 4100-4108, 2002.
29. Thompson, J., Guichard, S. M., Cheshire, P. J., Richmond, L. B., Poquette, C. A., Ragsdale, S. T., Webber, B., Lorsbach, R., Danks, M. K., and Houghton, P. J. Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother. Pharmacol., 47: 211-221, 2001.
30. Nikas, D. C., Foley, J. W., and Black, P. M. Fluorescent imaging in a glioma model in vivo. Lasers Surg. Med., 29: 11-17, 2001.
31. Yang, M., Baranov, E., Jiang, P., Sun, F. X., Li, X. M., Li, L., Hasegawa, S., Bouvet, M., Al Tuwaijri, M., Chishima, T., Shimada, H., Moossa, A. R., Penman, S., and Hoffman, R. M. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc. Natl. Acad. Sci. USA, 97: 1206-1211, 2000.
32. Moats, R., Ma, L. Q., Wajed, R., Sugiura, Y., Lazaryev, A., Tyszka, M., Jacobs, R., Fraser, S., Nelson, M. D., Jr., and DeClerck, Y. A. Magnetic resonance imaging for the evaluation of a novel metastatic orthotopic model of human neuroblastoma in immunodeficient mice. Clin. Exp. Metastasis, 18: 455-461, 2000.
33. Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., and Weinberg, R. A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet., 7: 353-361, 1994.
34. Largaespada, D. A., Brannan, C. I., Jenkins, N. A., and Copeland, N. G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet., 12: 137-143, 1996.
35. Zhang, Y. Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., and Clapp, D. W. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med., 187: 1893-1902, 1998.
36. Mahgoub, N., Taylor, B. R., Gratiot, M., Kohl, N. E., Gibbs, J. B., Jacks, T., and Shannon, K. M. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 94: 2469-2476, 1999.
37. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G., and Bishop, J. M. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J., 16: 2985-2995, 1997.
38. Norris, M. D., Burkhart, C. A., Marshall, G. M., Weiss, W. A., and Haber, M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med. Pediatr. Oncol., 35: 585-589. 2000.
39. Burkhart, C. A., Norris, M. D., Marshall, G. M., Weiss, W. A., Mili, M., and Haber, M. Reduction of neuroblastoma tumorigenesis following N-myc antisense treatment in a transgenic mouse model. Proc. Am. Assoc. Cancer Res., 43: 857, 2002.
40. Weeraratna, A. T., Dalrymple, S. L., Lamb, J. C., Denmeade. S. R., Miknyoczki, S., Dionne, C. A., et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin. Cancer Res. 7: 2237-2245, 2001.
41. Levis, M., Allebach, J., Tse, K. F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. A. FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 99: 3885-3891, 2002.
42. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J Med., 344: 1031-1037, 2001.
43. Demetri, G. D. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options. Semin. Oncol., 28: 19-26, 2001.
44. George, D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin. Oncol., 28: 27-33, 2001.
45. Kirstein, M. N., Houghton, P. J., Cheshire, P. J., Richmond, L. B., Smith, A. K., Hanna, S. K., and Stewart, C. F. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res., 7: 358-366, 2001.
46. Parman, T., Wiley, M. J., and Wells, P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med., 5: 582-585, 1999.
47. Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M., Arbuck, S. G., Travis, R., Sausville, E. A., and Houghton, P. J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res., 7: 1758-1764, 2001.
48. Cho, Y. S., Kim, M. K., Cheadle, C., Neary, C., Becker, K. G., and Cho-Chung, Y. S. Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl. Acad. Sci. USA, 98: 9819-9823, 2001.
49. Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., Kalyandrug, S., Christian, M., Arbuck, S., Hollingshead, M., and Sausville, E. A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer, 84: 1424-1431, 2001.
50. Takimoto, C. H. Why drugs fail: of mice and men revisited. Clin. Cancer Res., 7: 229-230, 2001.
51. Khanna, C., Prehn, J., Yeung, C., Caylor, J., Tsokos, M., and Helman, L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis, 18: 261-271, 2000.
52. Khanna, C., Khan, J., Nguyen, P., Prehn, J., Caylor. J., Yeung, C., Trepel, J., Meltzer, P., and Helman, L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res., 61: 3750-3759, 2001.
53. Uckun, F. M., Manivel, C., Arthur, D., Chelstrom, L. M., Finnegan, D., Tuel-Ahlgren, L., Irvin, J. D., Myers, D. E., and Gunther, R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood, 79: 2201-2214, 1992.
54. Waddick, K. G., Myers, D. E., Gunther, R., Chelstrom, L. M., Chandan-Langlie, M., Irvin, J. D., Tumer, N., and Uckun, F. M. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood, 86: 4228-4233, 1995.
55. Waurzyniak, B., Schneider, E. A., Tumer, N., Yanishevski. Y., Gunther, R., Chelstrom, L. M., Wendorf, H., Myers, D. E., Irvin, J. D., Messinger, Y., Ek, O., Zeren, T., Langlie. M. C., Evans, W. E., and Uckun, F. M. In vivo toxicity, phamacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin. Cancer Res., 3: 881-890, 1997.
56. Hare, C. B., Elion, G. B., Houghton, P. J., Houghton, J. A., Keir, S., Marcelli, S. L., Bigner, D. D., and Friedman, H. S. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 39: 187-191, 1997.
57. Friedman, H. S., Dolan, M. E., Pegg, A. E., Marcelli, S., Keir, S., Catino, J. J., Bigner. D. D., and Schold, S. C., Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
58. Middlemas, D. S., Stewart, C. F., Kirstein, M. N., Poquette, C., Friedman, H. S., Houghton, P. J., and Brent, T. P. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin. Cancer Res., 6: 998-1007, 2000.
59. Aaron, R. H., Elion, G. B., Colvin, O. M., Graham, M., Keir, S., Bigner, D. D., and Friedman, H. S. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother. Pharmacol., 35: 127-131, 1994.
60. Boland, I., Vassal, G., Morizet, J., Terrier-Lacombe, M. J., Valteau-Couanet, D., Kalifa, C., Hartmann, O., and Gouyette, A. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br. J. Cancer. 79: 787-792, 1999.
61. Fontaniere, C., Terrier-Lacombe. M. J., Santos, A., Aubert, G., Morizet, J., Jimeno, J. M., Faircloth, G., and Vassal, G. Antitumor Activity of Et-743 (ecteinascidin-743) in neuroblastoma and medulloblastoma xenografts. Proc. Am. Assoc. Cancer Res., 42: 88, 2001.
62. Vassal, G., Boland, I., Santos, A., Bissery, M. C., Terrier-Lacombe, M. J., Morizet, J., Sainte-Rose, C., Lellouch-Tubiana, A., Kalifa, C., and Gouyette, A. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int. J. Cancer, 73: 156-163, 1997.
63. Engler, S., Thiel, C., Forster, K., David, K., Bredehorst, R., and Juhl, H. A novel metastatic animal model reflecting the clinical appearance of human neuroblastoma: Growth arrest of orthotopic tumors by natural, cytotoxic human immunoglobulin M antibodies. Cancer Res., 61: 2968-2973, 2001.
64. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-431, 1997.
65. Thompson, J., Zamboni, W. C., Cheshire, P. J., Richmond, L., Luo, X., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of oral irinotecan against neuroblastoma xenografts. Anticancer Drugs, 8: 313-322, 1997.
66. Weitman, S., Barrera, H., Moore, R., Gonzalez, C., Marty, J., Hilsenbeck, S., MacDonald, J. R., Waters, S. J., and Von Hoff, D. MGI 114: Augmentation of antitumor activity when combined with topotecan. J. Pediatr. Hematol. Oncol., 22: 306-314, 2000.
67. Thompson, J., George, E. O., Poquette, C. A., Cheshire, P. J., Richmond, L. B., de Graaf, S. S., Ma, M., Stewart, C. F., and Houghton, P. J. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin. Cancer Res., 5: 3617-3631, 1999.
68. Anderson, P. M., Meyers, D. E., Hasz, D. E., Covalcuic, K., Saltzman, D., Khanna, C., and Uckun, F. M. In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein. Cancer Res., 55: 1321-1327, 1995.
69. Ek, O., Waurzyniak, B., Myers, D. E., and Uckun, F. M. Antitumor activity of TP3 (anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma. Clin. Cancer Res., 4: 1641-1647, 1998.
70. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
71. Houghton, P. J., Cheshire, P. J., Hallman, J. C., Bissery, M. C., Mathieu-Boue, A., and Houghton, J. A. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res., 53: 2823-2829, 1993.
72. Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L., and Adams, J. M. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med., 167: 353-371, 1988.
73. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318: 533-538, 1985.
74. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., and Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev., 13: 2670-2677, 1999.
75. Schmitt, C. A., Rosenthal, C. T., and Lowe, S. W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat. Med., 6: 1029-1035, 2000.
76. Schmitt, C. A., and Lowe, S. W. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol. Dis., 27: 206-216, 2001.
77. Ding, H., Roncari, L., Shannon, P., Wu, X., Lau, N., Karaskova, J., Gutmann, D. H., Squire, J. A., Nagy, A., and Guha, A. Astrocytespecific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res., 61: 3826-3836, 2001.
78. Reilly, K. M., Loisel, D. A., Bronson, R. T., McLaughlin, M. E., and Jacks, T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat. Genet., 26: 109-113, 2000.
79. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H., and Sherr, C. J. Tumor spectrum in ARF-deficient mice. Cancer Res, 59: 2217-2222, 1999.
80. Maddalena, A. S., Hainfellner, J. A., Hegi, M. E., Glatzel, M., and Aguzzi, A. No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathol., 9: 627-637, 1999.
81. Goodrich, L. V., Milenkovic,. L., Higgins, K. M., and Scott, M. P. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science (Wash. DC), 277: 1109-1113, 1997.
82. Hahn, H., Wojnowski, L., Specht, K., Kappler, R., Calzada-Wack, J., Potter, D., Zimmer, A., Muller, U., Samson, E., Quintanilla-Martinez, L., and Zimmer, A. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J. Biol. Chem., 275: 28341-28344, 2000.
83. Wetmore, C., Eberhart, D. E., and Curran, T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res., 60: 2239-2246, 2000.
84. Wetmore, C., Eberhart, D. E., and Curran, T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res., 61: 513-516, 2001.
85. Krynska, B., Otte, J., Franks, R., Khalili, K., and Croul, S. Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals. Oncogene, 18: 39-46, 1999.
86. Gan, D. D., Reiss, K., Carrill, T., Del Valle, L., Croul, S., Giordano, A., Fishman, P., and Khalili, K. Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus. Oncogene, 20: 4864-4870, 2001.
87. Dobson, C. L., Warren, A. J., Pannell, R., Forster, A., Lavenir, I., Corral, J., Smith, A. J., and Rabbitts, T. H. The MLL-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis. EMBO J., 18: 3564-3574, 1999.
88. Heisterkamp, N., Jenster, G., ten Hoeve, J., Zovich, D., Pattengale, P. K., and Groffen, J. Acute leukaemia in bcr/abl transgenic mice. Nature (Lond.), 344: 251-253, 1990.
89. Voncken, J. W., Griffiths, S., Greaves, M. F., Pattengale, P. K., Heisterkamp, N., and Groffen, J. Restricted oncogenicity of BCR/ABL p190 in transgenic mice. Cancer Res., 52: 4534-4539, 1992.
90. Reichert, A., Heisterkamp, N., Daley, G. Q., and Groffen, J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood, 97: 1399-1403, 2001.
91. Hemmeryckx, B., van Wijk, A., Reichert, A., Kaartinen, V., de Jong, R., Pattengale, P. K., Gonzalez-Gomez, I., Groffen, J., and Heisterkamp, N. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res., 61: 1398-1405, 2001.
92. Rhoades, K. L., Hetherington, C. J., Harakawa, N., Yergeau, D. A., Zhou, L., Liu, L. Q., Little, M. T., Tenen, D. G., and Zhang, D. E. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood, 96: 2108-2115, 2000.
93. Yuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., and Zhang, D. E. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Natl. Acad. Sci. USA, 98: 10398-10403, 2001.
94. He, L. Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G., and Pandolfi, P. P. Acute leukemia with promyelocytic features in PML/RARα transgenic mice. Proc. Natl. Acad. Sci. USA, 94: 5302-5307, 1997.
95. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins. Proc. Natl. Acad. Sci. USA, 97: 10173-10178, 2000.
96. Kogan, S. C., Brown, D. E., Shultz, D. B., Truong, B. T., Lallemand-Breitenbach, V., Guillemin, M. C., Lagasse, E., Weissman, I. L., and Bishop, J. M. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor α chimeric protein (PMLRARα) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med., 193: 531-544, 2001.
97. Rego, E., Wang, Z., Peruzzi, D., He, L., Cordon-Cardo, C., and Pandolfi, P. Role of promyelocytic leukemia (PML) protein in tumor suppression. J. Exp. Med., 193: 521-530, 2001.
98. Condorelli, G. L., Facchiano, F., Valtieri, M., Proietti, E., Vitelli, L., Lulli, V., Huebner, K., Peschle, C., and Croce, C. M. T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res., 56: 5113-5119, 1996.
99. Kelliher, M. A., Seldin, D. C., and Leder, P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J., 15: 5160-5166, 1996.
100. O'Neil, J., Billa, M., Oikemus, S., and Kelliher, M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene, 20: 3897-3905, 2001.
101. Aplan, P. D., Jones, C. A., Chervinsky, D. S., Zhao, X., Ellsworth, M., Wu. C., McGuire, E. A., and Gross, K. W. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO-to generate T-cell malignancies in transgenic mice. EMBO J., 16: 2408-2419, 1997.
102. Larson, R. C., Lavenir, I., Larson. T. A., Baer, R., Warren, A. J., Wadman, I., Nottage, K., and Rabbitts, T. H. Protein dimerization between Lmo2 (Rbtn2) and Tall alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J., 15: 1021-1027, 1996.
103. Yan, W., Young, A. Z., Soares, V. C., Kelley, R., Benezra, R., and Zhuang, Y. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell. Biol., 17: 7317-7327, 1997.
104. Bain, G., Engel, I., Robanus Maandag, E. C., te Riele, H. P., Voland, J. R., Sharp, L. L., Chun, J., Huey, B., Pinkel, D., and Murre, C. E2A deficiency leads to abnormalities in αβ T-cell development and to rapid development of T-cell lymphomas. Mol. Cell. Biol., 17: 4782-4791, 1997.
105. Roberts, C. W., Galusha, S. A., McMenamin, M. E., Fletcher, C. D., and Orkin, S. H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl. Acad. Sci. USA, 97: 13796-13800, 2000.
106. Guidi, C. J., Sands, A. T., Zambrowicz, B. P., Turner, T. K., Demers, D. A., Webster, W., Smith. T. W., Imbalzano, A. N., and Jones, S. N. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol. Cell. Biol., 21: 3598-3603, 2001.
107. Klochendler-Yeivin, A., Fiette, L., Barra, J., Muchardt. C., Babinet, C., and Yaniv, M. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep., 1: 500-506, 2000.
108. Cichowski, K., Shih, T. S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin, M. E., Bronson, R. T., and Jacks, T. Mouse models of tumor development in neurofibromatosis type 1. Science (Wash. DC), 286: 2172-2176, 1999.
109. Vogel, K. S., Klesse, L. J., Velasco-Miguel, S., Meyers, K., Rushing, E. J., and Parada, L. F. Mouse tumor model for neurofibromatosis type 1. Science (Wash. DC), 286: 2176-2179, 1999.